ライフサイエンスコーパス: PHQ

1 PHQ-2 scores were extracted from the answers to the firs

2 PHQ-9 data were available for 614 patients at 3 months a

3 nts [7.3]; BA 7.8 [6.5], mean difference 0.0 PHQ-9 points [-1.5 to 1.6], p=0.99).

4 8.4 PHQ-9 points [7.0], mean difference 0.1 PHQ-9 points [95% CI -1.3 to 1.5], p=0.89; PP: CBT 7.9 P

5 re extracted from the answers to the first 2 PHQ-9 questions.

6 en patients (Patient Health Questionnaire-2 [PHQ-2], GAD-2, and an item about panic attacks), and a d

7 (mITT: CBT 8.4 PHQ-9 points [SD 7.5], BA 8.4 PHQ-9 points [7.0], mean difference 0.1 PHQ-9 points [95

8 BA was non-inferior to CBT (mITT: CBT 8.4 PHQ-9 points [SD 7.5], BA 8.4 PHQ-9 points [7.0], mean d

9 The non-inferiority margin was 1.9 PHQ-9 points.

10 ts [95% CI -1.3 to 1.5], p=0.89; PP: CBT 7.9 PHQ-9 points [7.3]; BA 7.8 [6.5], mean difference 0.0 PH

11 an 14 on the Patient Health Questionnaire 9 (PHQ-9) indicating moderately severe to severe depression

12 on severity [Patient Health Questionnaire 9 (PHQ-9) score of <19 vs >/=19], antidepressant use, and r

13 and email, a Patient Health Questionnaire 9 (PHQ-9) score of at least 10, and a confirmed diagnosis o

14 ssion on the Patient Health Questionnaire 9 (PHQ-9) were randomised to either HAP plus enhanced usual

15 sured by the Patient Health Questionnaire 9 (PHQ-9), a self-report questionnaire validated to correla

16 eks with the Patient Health Questionnaire-9 (PHQ-9) and was scored diagnostically by using Diagnostic

17 d the use of Patient Health Questionnaire-9 (PHQ-9) as depression severity dimension) may improve cli

18 essed by the Patient Health Questionnaire-9 (PHQ-9) depression scale compared with 50% of EUC patient

19 uracy of the Patient Health Questionnaire-9 (PHQ-9) depression screening tool.

20 nistered the Patient Health Questionnaire-9 (PHQ-9) during the index AMI admission.

21 ompleted the Patient Health Questionnaire-9 (PHQ-9), which included Item 9 that asks patients if they

22 ion with the Patient Health Questionnaire-9 (PHQ-9).

23 >/=10 on the Patient Health Questionnaire-9 (PHQ-9).

24 , defined by Patient Health Questionnaire-9 [PHQ-9] score) conducted from June 2010 through March 201

25 A PHQ motif near the amino termini of gammaretroviral enve

26 tly transactivated by adding to the assays a PHQ-containing SU or receptor-binding subdomain (RBD) de

27 Depression was defined by a PHQ-9 score of >/=10.

28 documented in the medical records despite a PHQ score >/=10.

29 0 individuals and 170 (29%) of the 585 had a PHQ diagnosis.

30 and higher remission (147 [64%] of 230 had a PHQ-9 score of <10 in the HAP plus EUC group vs 91 [39%]

31 A random sample of those with a PHQ-9 score that was less than 9 were selected for a CID

32 c-statistics the potential of both PHQ-2 and PHQ-9 to predict death and hospitalization was similar.

33 To analyze associations of PHQ-2 and PHQ-9 with both, death and rehospitalization, univariabl

34 Both, PHQ-2 and PHQ-9, predicted death in univariable analysis (hazard r

35 sociated with underreporting on the AAFQ and PHQ but overreporting on PAR.

36 r analysis of pooled questions of CNS-LS and PHQ-9 identified three underlying factors (laughter, cry

37 the two self-report instruments (CNS-LS and PHQ-9) discriminate well between PBA and depression, the

38 Mean PCS, MCS, and PHQ-9 scores were relatively stable over a median of 3 y

39 reporting decreased with age for the PAR and PHQ.

40 (R(2) = 7.6, 4.8, and 3.4 for AAFQ, PAR, and PHQ, respectively).

41 ) to 79.4, 67.8, and 68.7 for AAFQ, PAR, and PHQ, respectively.

42 tified by site and minimised by practice and PHQ-9 score.

43 s responding to the intervention (defined as PHQ-9 <10 and reduction in PHQ-9 of >/=5 points) at 4 mo

44 There was good agreement between PHQ diagnoses and those of independent mental health pro

45 firmed by c-statistics the potential of both PHQ-2 and PHQ-9 to predict death and hospitalization was

46 Both, PHQ-2 and PHQ-9, predicted death in univariable analysis

47 ysis predicts Cu-PHE, Cu-PHQ, Cd-PHE, and Cd-PHQ mixtures at the Canadian Water Quality Guideline con

48 r all Cu-PHE, Cu-PHQ, and several Cd-PHE, Cd-PHQ, and Ni-PHE mixtures.

49 tions in or adjacent to the highly conserved PHQ motif present at the N terminus of the envelope surf

50 le and more feasible than the time-consuming PHQ-9 to identify patients at an increased risk of adver

51 ore-than-additive mortality of Cu-PHE and Cu-PHQ mixtures.

52 ve lethality was observed for all Cu-PHE, Cu-PHQ, and several Cd-PHE, Cd-PHQ, and Ni-PHE mixtures.

53 Our analysis predicts Cu-PHE, Cu-PHQ, Cd-PHE, and Cd-PHQ mixtures at the Canadian Water Q

54 Among patients with baseline depression (PHQ-9 score > or = 10), there was greater improvement in

55 ry version II and remission from depression (PHQ-9 score of <10) at 3 months in the intention-to-trea

56 patients with AMI having: (1) no depression (PHQ-9<10; reference); (2) treated depression; and (3) un

57 estionnaire includes measures of depression (PHQ-9) and substance abuse (ASSIST).

58 e proportion of individuals with depression (PHQ-9 score >9) who sought treatment for symptoms of dep

59 on meeting criteria for depressive disorder (PHQ-9 score >/=10) at 4- and 12-month follow-up.

60 ain Intensity subscale, and -3.7 vs -1.2 for PHQ-9.

61 ee host-range groups, A, B, and C, lack full PHQ motifs, but most members have an H residue at positi

62 However, PHQ increased the tissue concentration of Cu in juvenile

63 ement was also found for 5-point decrease in PHQ-9 score among 72.2% of intervention patients compare

64 ed with survival after adding improvement in PHQ-9 scores to the survival model.

65 However, improvement in PHQ-9 scores was not associated with improved survival,

66 assigned to EPC had greater improvements in PHQ-9 scores at 12 weeks (P < .001); among patients with

67 ntion (defined as PHQ-9 <10 and reduction in PHQ-9 of >/=5 points) at 4 months after randomisation.

68 response was considered >/= 50% reduction in PHQ-9 scores at 12 weeks.

69 e proportion with scores >/=15 on the 9-item PHQ dropped from 15.1% [38 of 252] to 8.0% [18 of 225] a

70 ession (Patient Health Questionnaire 9-item [PHQ-9] score >/=10) on 2 occasions or who screened posit

71 for age, sex, and the other screening items, PHQ-2 items independently predicted depression (little i

72 Collaborative care resulted in lower PHQ-9 scores vs usual care at 4-month follow-up (mean sc

73 statistically significant reduction in mean PHQ-9 depression scores at 3 months for acupuncture (-2.

74 ment differences remained at 12 months (mean PHQ-9 score with collaborative care, 5.93 vs with usual

75 The mean PHQ-9 score was 7, corresponding to a symptom severity o

76 Overall, 759 (18.7%) patients met PHQ-9 criteria for depression and 231 (30.4%) were treat

77 The proportion of participants who met PHQ-9 criteria for depression increased from 3.9% prior

78 117 (32%) of the 363 patients with 1 or more PHQ diagnoses not previously recognized.

79 ssionals (for the diagnosis of any 1 or more PHQ disorder, kappa = 0.65; overall accuracy, 85%; sensi

80 To analyze associations of PHQ-2 and PHQ-9 with both, death and rehospitalization,

81 There were no effects on PHQ-8 measured depression score at the 12-week follow-up

82 es) and higher order products observed (PHA, PHQ, and LMW oxo- and dicarboxylic acids).

83 h phenanthrene (PHE) or phenanthrenequinone (PHQ) using the aquatic amphipod Hyalella azteca.

84 r phenanthrene (PHE) or phenanthrenequinone (PHQ).

85 AD beginning with a 4-item scale (GAD-2 plus PHQ-2).

86 In clinical practice, PHQ-2 screening seems thus sufficiently reliable and mor

87 th Initiative Personal Habits Questionnaire (PHQ).

88 tionnaire- the Patient Health Questionnaire (PHQ 15) (plus enhanced iterations including an additiona

89 The Patient Health Questionnaire (PHQ) depression and anxiety modules were administered at

90 g outcomes and Patient Health Questionnaire (PHQ) for depression).

91 sion using the Patient Health Questionnaire (PHQ) has been extensively examined.

92 0.90) and the Patient Health Questionnaire (PHQ)-9 (sensitivity: 0.86; 95% CI 0.70 to 0.94; specific

93 ssed using the Patient Health Questionnaire (PHQ).

94 of the 2-item patient health questionnaire (PHQ-2) versus that of the 9-item version (PHQ-9) to pred

95 erence in mean Patient Health Questionnaire (PHQ-9) scores at 3 months with secondary analyses over 1

96 n scale of the Patient Health Questionnaire (PHQ-9) was significantly higher at baseline (median, 6.0

97 r above on the Patient Health Questionnaire (PHQ-9) were administered to the standardized computer-as

98 ing the 9-item Patient Health Questionnaire (PHQ-9), a series of psychological traits, and the 5-HTTL

99 e (CNS-LS) and Patient Health Questionnaire (PHQ-9), respectively) were obtained from consecutive pat

100 sured with the Patient Health Questionnaire (PHQ-9).

101 on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27).

102 ng the 8-item Personal Health Questionnaire [PHQ-8]; range, 0-24, higher scores worse) and family-rep

103 ured using the Patient Health Questionnaire [PHQ]-9), and mental health literacy.

104 ophoric mono- and polyhydroxylated quinones (PHQ), a different channel produces oxo- and dicarboxylic

105 =50% decrease on the CDRS-R), and remission (PHQ-9 score <5).

106 ealth Questionnaire 9-item depression scale (PHQ-9), patient-reported satisfaction with their blood-p

107 sease reported higher symptoms count scores (PHQ 15: 5.6 (95% CI 5.4 to 5.8) vs 4.2 (4.1 to 4.4) p<0.

108 For the "standard" PHQ-9 cutoff of 10, accuracy results had been published

109 e 199 participants with depressive symptoms (PHQ score > or = 10) and 6.7% among the 818 participants

110 icipants, 201 (20%) had depressive symptoms (PHQ score > or =10).

111 The PHQ-9 depression score increased from 2.4 prior to inter

112 , 2.91; 95% CI, 1.20-4.63; P < .001) and the PHQ-9 (difference, 2.12; 95% CI, 0.68-3.56; P = .004).

113 me measures were depression (measured by the PHQ-2 depression scale) and anxiety (measured by the two

114 ession at 12-week follow-up, measured by the PHQ-8 (secondary outcome).

115 program were eligible, if they completed the PHQ-9 during baseline assessment.

116 While there is promising data for the PHQ-2 in other populations, it performed less well than

117 = 0.14 (90% CI, -0.05 to 0.33), and for the PHQ-9 it was d = -0.02 (90% CI, -0.20 to 0.17).

118 physicians reported that routine use of the PHQ would be useful, new management actions were initiat

119 ificantly lowered depression symptoms on the PHQ-9 at 6 weeks and 6 months compared with HealthWatch

120 rty percent of patients scored >or=10 on the PHQ-9 during at least one clinic visit, which correspond

121 n Inventory-II (BDI-II) and remission on the PHQ-9.

122 ce-to-face CBT on the Ham-D (P = .22) or the PHQ-9 (P = .89).

123 liminary data suggests the CESD, HDRS or the PHQ-9 as the most promising options.

124 The two-item PHQ2, the nine-item PHQ9, the PHQ DSM-IV algorithm, and the two-step PHQ2 then PHQ9.

125 time required of the physician to review the PHQ was far less than to administer the original PRIME-M

126 Four main versions of scoring the PHQ exist.

127 Our study suggests that the PHQ has diagnostic validity comparable to the original c

128 proteins with an insertion C-terminal to the PHQ motif (GALV I(10)) bind Pit1 but fail to infect cell

129 ome was depression symptoms according to the PHQ-9 at 12 months.

130 10 prespecified secondary outcomes were the PHQ-9 score at 12-month follow-up and the proportion mee

131 When the PHQ-9 was highly sensitive, authors more often reported

132 In samples where the PHQ-9 was poorly sensitive at the standard cutoff, autho

133 attacks), and a diagnostic evaluation using PHQ-9 and the Primary Care Evaluation of Mental Disorder

134 with patients receiving treatment as usual (PHQ-9 beta, -0.177 [95% CI, -0.295 to -0.060]; P = .003)

135 e (PHQ-2) versus that of the 9-item version (PHQ-9) to predict death or rehospitalization.

136 Patients with PHQ diagnoses had more functional impairment, disability

137 nd health care use than did patients without PHQ diagnoses (for all group main effects, P<.001).